
|Videos|January 4, 2019
Findings for Cemiplimab in Advanced or Recurrent Cervical Cancer
Author(s)Danny Rischin, MD, MBBS, FRACP
Danny Rischin, MD, MBBS, FRACP, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
Advertisement
Danny Rischin, MD, MBBS, FRACP, director of the Division of Cancer Medicine and head of the Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discussed the results from a phase II trial looking at cemiplimab (Libtayo) in patients with advanced or recurrent cervical cancer.
Cemiplimab, a PD-1 monoclonal antibody, was given as a single agent, as well as in combination with radiotherapy in a second cohort. Each of the 2 cohorts had a partial response, Rischin notes.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































